TEM · Tempus AI, Inc. · Stock research

Current Thesis

The leg being bought since 2026-08-19 is not Tempus's own P&L — it is a read-through. Merck and Moderna announced that the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met its recurrence-free-survival primary endpoint and its distant-metastasis-free-survival key secondary endpoint in resected stage IIB–IV melanoma (1,137 patients randomised 2:1). Individualised neoantigen therapy requires tumour sequencing and ultrasensitive residual-disease monitoring per patient. Tempus agreed on 2026-07-20 to buy Personalis, whose NeXT Personal MRD assay sits in that workflow, for $16.25 per share, an enterprise value of $1.5B net of Tempus's existing stake. The market repriced Tempus as the listed supplier of the diagnostic layer under a drug class that had never before produced a positive Phase 3. Price closed at $72.69 on 2026-08-21 with RSI(14) at 82.4, having traded at a $53.90 weighted-average print on 2026-08-14 (a director's Form 4). That is roughly a one-third move in five sessions, on a deal that has not closed and a supply relationship that has not been contracted publicly.

Bullish and bearish views on Tempus AI, Inc.

The model's bull view on Tempus AI, Inc. (TEM), in brief: Q2 2026 (reported 2026-07-30): revenue $382.5M, up 22% year over year; Diagnostics $289.3M (+20%), Data & Applications $93.2M (+28%). The bear view: The re-rating is second-order. Neither Merck nor Moderna named Tempus or Personalis as a commercial diagnostic partner in the 2026-08-19 topline release. The connection is technological, not a disclosed contract with disclosed economics. Sell-side marks straddle the price… Both cases follow in full.

Bull Case

• Q2 2026 (reported 2026-07-30): revenue $382.5M, up 22% year over year; Diagnostics $289.3M (+20%), Data & Applications $93.2M (+28%). First GAAP-profitable quarter, net income $5.6M against a prior-year loss.
• FY2026 guidance raised to $1.595–1.605B (about 25% growth) with adjusted EBITDA of roughly $65M, a $72M swing versus 2025. Management attributed part of the raise to roughly $200M of newly signed data and applications licences.
• FDA approval of the tumour-only xT CDx enables unified ADLT pricing, which the company sizes at an estimated $85M annualised revenue uplift beginning in 2027 — a reimbursement step, not a volume assumption.
• The Personalis agreement carries structural support: Merck holds roughly 13% of Personalis voting power and has agreed to vote in favour. Merck is also the sponsor of the trial that just re-rated the sector.
• Platform proof points landed in the same month: PRISM2 pathology foundation-model results published in Nature Medicine on 2026-08-04, and CellCarta named Tempus the second commercial laboratory partner in its companion-diagnostics commercialisation network on 2026-08-06.
• BTIG maintained Buy and raised its target to $80 on 2026-08-20, the first published target above the reference close.

Bear Case

• The re-rating is second-order. Neither Merck nor Moderna named Tempus or Personalis as a commercial diagnostic partner in the 2026-08-19 topline release. The connection is technological, not a disclosed contract with disclosed economics.
• Sell-side marks straddle the price awkwardly. Piper Sandler cut to $56 with a Neutral rating on 2026-08-04; HC Wainwright kept Buy but cut to $56 on 2026-08-03; BTIG itself cut to $70 on 2026-08-03 before raising to $80 on 2026-08-20. Two of the four most recent targets sit roughly 23% below the 2026-08-21 close.
• The acquisition is stock-funded (Tempus may elect up to 50% cash), with a floating exchange ratio capped at 0.3356. Share count is not fixed until close, targeted for late 2026 or early 2027, and is contingent on Personalis shareholder approval, S-4 effectiveness, Nasdaq listing and antitrust clearance.
• Insider supply into the move: director Nadja West sold 3,000 Class A shares at a $53.90 weighted average on 2026-08-14 under a 10b5-1 plan adopted 2026-05-15, retaining 34,981 shares. Coverage on 2026-08-22 flagged contemporaneous filings from several officers.
• Price is 29.6% below the $103.25 52-week high despite a 57.4% three-month gain, so the current leg is a recovery inside a broken 2026 range, not a breakout to new highs.
• Macro backdrop for long-duration, barely-profitable growth is unhelpful: long-end Treasury yields snapped back toward 20-month highs on 2026-08-20.

Setup & Price Structure

The narrative is accelerating, dated to 2026-08-19. What dates it — a first-in-class Phase 3 readout on 2026-08-19, a target raise the next session, and three separate retail-facing "what's driving the move" explainers in three consecutive sessions (2026-08-19, 2026-08-20, 2026-08-21). New attention, new headline supply, widening participation.

Crowding and positioning observables, stated without a verdict: RSI(14) at 82.4 on the 2026-08-21 close of $72.69; a roughly one-third advance in five sessions off the $53.90 area printed on 2026-08-14; retail-sentiment coverage clustering as above; insider sales dated 2026-08-14 and around it; and an all-stock acquisition that issues equity into the strength once it closes.

Structure: the gap that opened on 2026-08-19 has not been tested. The pre-catalyst shelf sits in the mid-$50s, which is also where two of four current sell-side targets cluster. Above, the unfilled reference is the $103.25 52-week high. One level here is contractual rather than technical: Personalis may terminate the merger if Tempus Class A trades below $46.00 before closing, which links Tempus's own quote to deal certainty.

Catalyst Calendar (next 30 days)

• ~2026-09 (est., date not announced): S-4 registration statement effectiveness and a Personalis definitive proxy setting the special-meeting date. Resolves the closing timetable.
• ~2026-09 (est., date not announced): Antitrust clearance for the Personalis transaction.
• Date not announced: Full INTerpath-001 data presentation at a medical meeting. Detailed hazard ratios and subgroup data are what would let the market size the addressable MRD volume rather than assume it.
• ~2026-11-05 (est.): Q3 2026 print — the first read on whether the raised $1.595–1.605B FY2026 guide holds.
• Late 2026 / early 2027 (company target): Personalis close.
• 2027 (company guidance): unified ADLT pricing for tumour-only xT CDx, an estimated $85M annualised uplift.

Nothing inside the next 30 days is a hard, dated binary. The move to date is running on a catalyst that already fired.

What Would Change Our Mind

The structural break is the 2026-08-19 gap. If Merck's or Moderna's commercial-launch disclosures name a different sequencing or MRD partner, or if the full INTerpath-001 presentation lands without any Personalis assay in the workflow, the read-through that produced this leg loses its factual anchor and the mid-$50s consolidation becomes the reference again. On price, a weekly close below $58 would retrace the entire post-readout advance and put the tape back where the 2026-08-04 Neutral target sits. A second condition worth watching is deal mechanics: any Personalis proxy disclosure that pushes the close past Q1 2027, or an antitrust second request, extends the window during which Tempus carries the dilution expectation without the revenue. Conversely, a disclosed commercial supply agreement with a named pharma sponsor would convert the inference into a contracted revenue line and would raise the bar for what counts as invalidation.

Correlation Notes

• PSNL is the tightest linkage: the 0.3356 maximum exchange ratio means Personalis trades as a levered proxy on Tempus's own quote until the vote, and the $46.00 walk-away right makes the relationship reflexive.
• MRNA and MRK are the upstream drivers of this leg. Any post-readout regulatory setback on intismeran, or a delay to the filing path, transmits straight to the Tempus read-through.
• MRD and liquid-biopsy comparables — Natera, Guardant Health, Exact Sciences — should move on the same neoantigen-vaccine logic. If they do not, the Tempus move is idiosyncratic and more likely flow-driven.
• Rate sensitivity: an unprofitable-until-this-quarter platform with a 2027 pricing catalyst prices as long duration. The 2026-08-20 move in long-end yields toward 20-month highs is the relevant macro cross-current.